National guidelines |
|
Cardiovascular risk and chronic kidney disease: cardio- and nephroprotection strategies
|
4-29 |
Calcimimetics advisory council |
|
A.Yu. Zemchenkov
The results of the advisory council of experts «Place of calcimimetics in modern clinical recommendations for mbd-ckd – in the light of new studies using cincalcet»
|
30-36 |
|
RESOLUTION OF ADVISORY COUNCIL OF NEPHROLOGISTS FROM MOSCOW, MOSCOW REGION, ST. PETERSBURG, SARATOV, SAMARA, AND YEKATERINBURG IN MOSCOW 05.03.2014 ON THE TOPIC: PLACE OF CALCIMIMETICS IN MODERN CLINICAL RECOMMENDATIONS FOR MBD-CKD IN THE LIGHT OF NEW STU
|
37-38 |
PHARMACOTHERAPY |
|
A.V. Scherbak, M.V. Lebedeva
Approaches to treatment of patients with uric acid dysmetabolism
|
39-41 |
ORIGINAL PAPERS |
|
S.N.Skornyakov, O.N. Zuban, B.I. Novikov, E.P. Borodin, L.V. Arkanov, I.D. Medvinsky, O.V. Fadina
Comparative clinical and age-related features and criteria for evaluating the results of treatment of urinary tract tuberculosis
|
42-47 |
|
E.G. Ovskaya
Dynamics of osteopontin levels during therapy with candesartan in patients on program hemodialysis
|
48-51 |
|
V.B. Borodulin, A.A. Protopopov, V.I. Goremykin, I.A. Utts, O.V. Shevchenko, A.S. Volkov, E.N. Bychkov, O.E. Losev, O.V. Nesterenko
Diagnosis of chronic kidney disease at an early stage
|
52-55 |
|
A.V. Vatazin, A.A. Sinyutin, A.B. Zulkarnayev, K.A. Patyukov, R.O. Kantaria, M. Krstic
Metabolic disturbances in the intra-and postoperative period in renal transplantation
|
56-60 |
|
Z.R. Bashirova, E.S. Vozdvizhenskaya, I.M. Osmanov
The clinical value of the determination of matrix metalloproteinases and their inhibitors in children with autosomal dominant polycystic kidney disease
|
61-63 |
|
M.M. Batiushin, D.G. Pasechnik, V.A. Chistiakov
IgM-Nephropathy
|
64-69 |
CASE REPORTS |
|
A.G. Yankovoy., A.V. Vatasin., A.A. Sinutin., A.A. Smoliakov., V.A. Stepanov
Intraperitoneal bleeding at late postoperative period in CAPD patient
|
70-72 |
Русский
